EGFR and lung carcinoma: Trisolini and colleagues then published the results of a randomized clinical trial, which randomized 126 patients with suspected lung cancer to EBUS with and without ROSE to determine the effect of ROSE on genotyping, which included EGFR and KRAS testing by next-generation sequencing (NGS), followed by ALK testing (FISH) for EGFR and KRAS wild-type disease.